Major international emergencies such as the COVID-19 pandemic and the ongoing conflict in Ukraine have led to supply chain disruptions for FDA-regulated companies. During this webinar, speakers will discuss: 1) specific impacts of supply chain disruptions on FDA-regulated industry; 2) findings from the FDA’s 2021 100-day review of supply chains and reports on outcomes one year later; 3) ways that companies can mitigate risks posed by unexpected shortages or problems getting access to components of regulated products from third-party manufacturers; 4) federal efforts to stimulate domestic manufacturing of critical medical products and other FDA-regulated components; and 5) how organizations have rethought and rebuilt their supply chains to be more agile, efficient, and sustainable.

Get Access

  • +$100 for nonmembers

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.


Christina Anderson Mooney, Senior Legal Director, Medtronic
Amy Norris, Executive Counsel, Clif Bar & Company and Member, FDLI Board of Directors
Howard R. Sklamberg, Partner, Life Sciences & Healthcare Regulatory, Arnold & Porter LLP
Moderated by Winston Kirton, Partner, BakerHostetler

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.


On-demand content can be played back on most devices.


CLE credit is not currently available for pre-recorded sessions.

Related Content